# Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma

> **NCT06431113** · PHASE3 · COMPLETED · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 40 (actual)

## Conditions studied

- Glaucoma
- Neuroprotection

## Interventions

- **COMBINATION_PRODUCT:** Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )

## Key facts

- **NCT ID:** NCT06431113
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-27
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431113, "Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06431113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*